Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
Background: Dopamine agonists (DA) are the first line therapy for prolactinoma and symptomatic hyperprolactinemia; use as an adjuvant treatment for acromegaly and Cushing's disease is rare. Some patients develop de novo psychiatric symptoms or have exacerbation of pre-existing conditions during...
Main Authors: | José Miguel Hinojosa-Amaya, Nathaniel Johnson, Christina González-Torres, Elena V. Varlamov, Christine G. Yedinak, Shirley McCartney, Maria Fleseriu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.579606/full |
Similar Items
-
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01) -
Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01) -
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
by: Sunita M C De Sousa
Published: (2023-01-01) -
Recent Progress in the Medical Therapy of Pituitary Tumors
by: Fabienne Langlois, et al.
Published: (2017-05-01) -
Dopamine Agonists for Pituitary Adenomas
by: Odelia Cooper, et al.
Published: (2018-08-01)